Griffin Perry

Griffin Perry

Auto-generated profile, based on publicly available information

Griffin Perry

Department of Medicine, Penn State Health Milton S. Hershey Medical Center

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Sage Open Medicine
Verified
Journal Article
Open access
KSKanwarpreet Singh Sandhu
Kanwarpreet Singh Sandhu
SKSiddarth Kumar
Siddarth Kumar
Keshav GargKeshav Garg
Keshav Garg
KAKanishk Aggarwal
Kanishk Aggarwal
MTMayank Tiwwary
Mayank Tiwwary
RJRohit Jain
Rohit Jain
The US opioid crisis has rapidly escalated over the past 4 decades, with a shifting profile of available substances contributing to rising fatalities. Leading this crisis is illicitly manufactured fentanyl, now increasingly adulterated with xylazine, a veterinary sedative not approved for human use. Despite a greater awareness in recent years regarding the vital role of naloxone in preventing fatal cases of overdose, xylazine has been associated with a sharp increase in overdose-related deaths due to its potent central nervous system effects. Recent data suggest a significant spread of xylazine, underscoring the importance of strategies to counteract fentanyl and implement aggressive supportive care for xylazine-fentanyl toxicity. This combination, often undetectable by standard drug tests, presents challenges in diagnosis and treatment of overdoses. These challenges have become relevant among young adults, a demographic particularly affected, underscoring the need for harm reduction measures and further research into the shifting patterns of fentanyl-related intoxication across the United States.

18 April 2026 in Annals of Medicine
Verified
Journal Article
Open access
RCRahul Chikatimalla
Rahul Chikatimalla
ASAshka Shah
Ashka Shah
TSTwinkle Shah
Twinkle Shah
GPGriffin Perry
Griffin Perry
HBHimanshi Banker
Himanshi Banker
RJRohit Jain
Rohit Jain
To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in stroke prevention. A narrative review was conducted by synthesising data from cardiovascular outcome trials, meta-analyses and mechanistic studies involving GLP-1RAs such as semaglutide, liraglutide and dulaglutide. The search included literature on ischaemic stroke incidence, molecular pathways and clinical outcomes associated with GLP-1RA therapy. GLP-1RAs exhibit multiple protective mechanisms, including anti-inflammatory, antioxidant, neuroprotective and endothelial-stabilising effects. Long-acting agents demonstrate superior efficacy in reducing nonfatal and ischaemic stroke risk, with relative risk reductions ranging from 15% to 39% across major trials. These benefits are observed independent of glycemic control and appear most prominent in patients with preserved renal function and shorter diabetes duration. In contrast, short-acting exendin-based GLP-1RAs show limited cerebrovascular benefit. Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities. GLP-1RAs offer significant promise as adjunctive pharmacotherapy for stroke prevention in individuals with T2DM. Their multifactorial benefits extend beyond glucose regulation and may influence clinical outcomes through systemic vascular and neuroprotective mechanisms. However, inconsistencies in trial outcomes and limited data in non-diabetic or high-risk populations underscore the need for targeted stroke-specific studies. Personalised treatment approaches and broader risk stratification may optimise their use in cerebrovascular disease management.